Retatrutide, a once-weekly injection, makes the body more efficient at regulating appetite, digestion, and energy expenditure by activating these three receptors: Glucose-dependent insulinotropic polypeptide (GIP) Glucagon-like peptide 1 (GLP-1) Glucagon (GCG) Phase-2 clinical trial data published in the New England Journal of Medicine showed that the drug is effective for weight loss
They generally cause no or mild gastrointestinal disease
Keep a symptom diary noting the timing of medications, meals, and any fluctuations in Parkinson's or diabetes symptoms, as this information helps clinicians make informed adjustments
Clinical Studies: Clinical trials, such as the STEP (Semaglutide Treatment Effect in People with Obesity) program, have shown promising results for this medication in promoting weight loss
Find a way to convert the image below into snappy text or a bulleted list
That page doesn't seem to exist